Kyowa Hakko Kirin Completes Construction of Biopharmaceutical API FacilityBy
Kyowa Hakko Kirin Co., Ltd. has completed the construction of an biopharmaceutical API manufacturing facility at its Takasaki site in Japan. The company invested 6 billion yen ($58.8 million) for the facility, which includes a 12,000-L bioreactors for recombinant animal cells as well as a purification facility with a large column. Operations are scheduled to begin the first half of 2016.
Source: Kyowa Hakko Kirin